Boiron SA Market Cap ($395.82 Million)
Market Cap & Net Worth: Boiron SA (BOI)
Boiron SA market cap. Boiron SA (PA:BOI) has a market capitalization of $395.82 Million (€338.56 Million) as of November 7, 2026. Listed on the PA stock exchange, this France-based company holds position #13148 globally and #200 in its home market, demonstrating a 5.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Boiron SA's stock price €19.50 by its total outstanding shares 17362275 (17.36 Million). Also see BOI cash flow metrics for how efficiently the company converts equity into cash flow.
Boiron SA Market Cap History (2015–2026)
Boiron SA market cap history from 2015 to 2026. Data shows change from $951.24 Million to $395.82 Million (-7.85% CAGR). Check BOI stock price for real-time trading data and today's change.
Index Memberships
Boiron SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$222.35 Billion | 0.18% | #70 of 119 |
|
CAC Small90
CACS
|
$35.74 Billion | 1.11% | #22 of 64 |
|
CAC All-Tradable
CACT
|
$2.82 Trillion | 0.01% | #130 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.82 Trillion | 0.01% | #130 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.82 Trillion | 0.01% | #130 of 179 |
|
CAC Health Care
FRHC
|
$266.99 Billion | 0.15% | #18 of 36 |
Weight: Boiron SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Boiron SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Boiron SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Boiron SA to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.23x
Boiron SA's market cap is 1.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.84x
Boiron SA's market cap is 18.84 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.10 Billion | $614.49 Million | $77.72 Million | 1.78x | 14.10x |
| 2017 | $992.68 Million | $617.54 Million | $78.24 Million | 1.61x | 12.69x |
| 2018 | $664.46 Million | $604.22 Million | $57.46 Million | 1.10x | 11.56x |
| 2019 | $513.08 Million | $557.12 Million | $40.63 Million | 0.92x | 12.63x |
| 2020 | $601.46 Million | $513.58 Million | $26.21 Million | 1.17x | 22.95x |
| 2021 | $532.57 Million | $455.20 Million | $28.56 Million | 1.17x | 18.65x |
| 2022 | $771.95 Million | $534.24 Million | $44.67 Million | 1.44x | 17.28x |
| 2023 | $785.74 Million | $493.25 Million | $35.83 Million | 1.59x | 21.93x |
| 2024 | $544.00 Million | $487.56 Million | $11.34 Million | 1.12x | 47.99x |
| 2025 | $615.04 Million | $501.11 Million | $32.64 Million | 1.23x | 18.84x |
Competitor Companies of BOI by Market Capitalization
Companies near Boiron SA in the global market cap rankings as of November 7, 2026. Also see Boiron SA total assets for a full breakdown of the balance sheet.
Key companies related to Boiron SA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #506 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #532 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #570 globally with a market cap of $46.85 Billion USD ( CN¥320.16 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #615 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #506 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #532 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.40 |
| #570 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.85 Billion | CN¥50.19 |
| #615 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €19.30 |
Market Capitalization of Boiron SA (2015–2026)
Market capitalization of Boiron SA from 2015 to today. Between 2015 and today, Boiron SA's market cap moved from $951.24 Million to $ 395.82 Million, with a yearly change of -7.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €395.82 Million | -35.64% |
| 2025 | €615.04 Million | +13.06% |
| 2024 | €544.00 Million | -30.77% |
| 2023 | €785.74 Million | +1.79% |
| 2022 | €771.95 Million | +44.95% |
| 2021 | €532.57 Million | -11.45% |
| 2020 | €601.46 Million | +17.22% |
| 2019 | €513.08 Million | -22.78% |
| 2018 | €664.46 Million | -33.06% |
| 2017 | €992.68 Million | -9.45% |
| 2016 | €1.10 Billion | +15.24% |
| 2015 | €951.24 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Boiron SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $395.82 Million USD |
| MoneyControl | $395.82 Million USD |
| MarketWatch | $395.82 Million USD |
| marketcap.company | $395.82 Million USD |
| Reuters | $395.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Boiron SA
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties compr… Read more